NAPNAP's Developmental-Behavioral & Mental Health SIG
We warmly welcome you to our SIG's collaborative resource site!
Please refer to our Terms of Use and Privacy Policy prior to accessing the site.
  • DBMH Resource
  • Topics
    • ADHD
    • Anxiety >
      • Generalized Anxiety Disorder
      • Selective Mutism
      • Separation Anxiety Disorder
      • Social Phobia Disorder
      • Specific Phobia
    • ASD
    • Bipolar
    • Cerebral Palsy
    • Cleft Lip or Palette
    • Communication Disorders
    • Depressive Disorders
    • Development >
      • Normal Development
      • Cognition, Social
      • Gross Motor
      • Speech, Language
    • Disruptive, Impulse-Control, and Conduct Disorders
    • Dissociative Identity Disorder
    • Eating & feeding disorders
    • Elimination Disorders >
      • Enuresis
      • Encopresis
    • Fetal Alcohol Spectrum Disorders
    • Gender Dysphoria
    • Genetic Disorders >
      • Down syndrome
      • DiGeorge
      • Fragile X
      • Klinefelter
      • Inborn errors of metabolism
      • Marfan
      • Mitochondrial
      • Lysosomal
      • Prader-Willi
      • Rett syndrome
      • Rubinstein-Taybi
      • Tay-Sachs
      • Turner syndrome
      • Williams syndrome
    • Habit Disorders
    • Intellectual Disabilities
    • Language Disorders
    • Learning Disabilities
    • OCD and Related
    • Schizophrenia Spectrum
    • Sensory Integration
    • Somatic Symptoms
    • Spina Bifida
    • Substance Use
    • Trauma or Stress-Related
  • By Age
    • Neonate-Infant
    • Toddler
    • School-Age
    • Adolescent
  • PC Integration
  • Training
  • Resources
  • Calendar

Down Syndrome (Trisomy 21)

There are three types of Down syndrome: trisomy 21 (nondisjunction) accounts for 95% of cases, translocation accounts for about 4% and mosaicism accounts for about 1% (NDSS, 2014). All are associated with varying levels of intellectual disability (typically mild to moderate), characteristic facies, and hypotonia in infancy. Approximately 50% of children born with trisomy 21 have a cardiac defect (ASD is most common). Approximately 15% of children with trisomy 21 have hypothyroidism. 

Screening

  • Sequential Integrated Screening: two-step, non-invasive screening available in some states.
          1. Step 1: Maternal blood test (PAPP-A (pappalysin 1, or pregnancy-associated plasma protein A) + hCG, and a fetal nuchal translucency
              ultrasound performed at between 10-14 weeks gestation
          2. Step 2: Maternal blood test (also known as a "quad screen") (alpha fetoprotein, unconjugated estriol, hCG, dimeric inhibin A)
              performed at between 15-20 weeks gestation.

Assessment

  • Amniocentesis
  • Chorionic Villus Sampling (CVS)
  • Ultrasound
Associated conditions to consider...
  • ADHD
  • Alzheimer's disease (increased risk and earlier than typical presentation)
  • Anesthesia
  • Autism
  • Atlantoaxial Instability
  • Blood Diseases
  • ​Celiac disease
  • Dental Issues
  • Ear, Nose & Throat Issues
  • Endocrine Issues
  • Gastrointestinal Issues
  • Cardiovascular complications
  • Mental Health (depression, OCD, behavioral issues are common)
  • Sleep Apnea
  • Vision Issues

Position Papers

Health care information for families of children with Down Syndrome (AAP, 2013)
File Size: 205 kb
File Type: pdf
Download File


Articles

  • Bull, M. (2011). Health Supervision for Children With Down Syndrome. Pediatrics, 128, 2. pp 393-404.

Resources

  • NDSS Overview Brochure
  • A Promising Future Together: A guide for new and expectant parents
  • Video: An evening with Dr. William Cohen
Organizations:
  • National Downs Syndrome Society
  • NDSS Affliates Programs, listings by state

    SUBMISSION OR EDIT ON THE PAGE

Submit
Please refer to our Terms of Use  and Privacy Policy prior to accessing the site.
DISCLAIMER: NAPNAP's DBMH SIG site is for informational and educational purposes only. All informational materials and guides on this site are offered "as is" and are NOT a substitute for medical advice, diagnostic analysis, or treatment planning by a licensed provider. Please note that the information found on this site is not a comprehensive review of any condition, drug, or body system; do not use it to replace clinical decision making. By accessing this resource, you agree that neither NAPNAP nor its SIG group editors will be legally held responsible for any clinical, professional or personal actions taken as a result of using this site.
Proudly powered by Weebly